Myeloma patients may receive many different treatments throughout their care. Patients’ real-world experiences of treatments tell us how treatments work in everyday life. Myeloma Patients Europe (MPE) wants to hear from myeloma patients about their experiences with some particular treatments:

• Bispecific antibodies (such as teclistamab or elranatamab)
• CAR T-cell therapy (such as cilta-cel or ide-cel)
• Antibody–drug conjugates (such as belantamab mafodotin)
• Selinexor (a selective inhibitor of nuclear export)

If you have had any these treatments and would be willing to share your experiences with us, please fill out the form below. Your insights are incredibly valuable and your participation will help us shape research, policy and future myeloma care across Europe.